Efficacy of Rivaroxaban (Xarelto) ± Aspirin in the Prevention of Major Adverse Cardiovascular Events
Loading...
Date of Award
Spring 2020
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Renee Langstaff, MSPAS, PA-C
Abstract
Coronary artery disease (CAD) is the leading cause of death in both sexes, accounting for a third of all deaths in developed countries. One of the mainstays in treatment in both CAD and peripheral arterial disease (PAD) is the prevention of thrombus formation using antiplatelets, with aspirin as the drug of choice. Currently, rivaroxaban, a direct factor Xa inhibitor, is being studied in patients with CAD and PAD. This review addresses the efficacy of rivaroxaban, with or without aspirin, in the prevention of major adverse cardiovascular events, in adults with CAD and PAD, compared to standard of care, aspirin.
Recommended Citation
Chen, Christina, "Efficacy of Rivaroxaban (Xarelto) ± Aspirin in the Prevention of Major Adverse Cardiovascular Events" (2020). Capstone Showcase. 59.
https://scholarworks.arcadia.edu/showcase/2020/pa/59
Additional Files
References page for poster.pdf (63 kB)Reference list
PICO Poster.pdf (11395 kB)
PDF of poster
Efficacy of Rivaroxaban (Xarelto) ± Aspirin in the Prevention of Major Adverse Cardiovascular Events
Coronary artery disease (CAD) is the leading cause of death in both sexes, accounting for a third of all deaths in developed countries. One of the mainstays in treatment in both CAD and peripheral arterial disease (PAD) is the prevention of thrombus formation using antiplatelets, with aspirin as the drug of choice. Currently, rivaroxaban, a direct factor Xa inhibitor, is being studied in patients with CAD and PAD. This review addresses the efficacy of rivaroxaban, with or without aspirin, in the prevention of major adverse cardiovascular events, in adults with CAD and PAD, compared to standard of care, aspirin.